| Market Size 2023 (Base Year) | USD 2.32 Billion |
| Market Size 2032 (Forecast Year) | USD 4.56 Billion |
| CAGR | 7.8% |
| Forecast Period | 2024 - 2032 |
| Historical Period | 2018 - 2023 |
As per the published report by Market Research Store, the global Implantable Insulin Pump Market size was estimated at USD 2.32 Billion in 2023 and is anticipated to reach USD 4.56 Billion by 2032, growing at a projected CAGR of 7.8%. The report provides a detailed analysis of the global market, including market trends, market dynamics, and market opportunities during the forecast period (2024-2032). It delves deeper into several market facets, such as market definition, size, growth, forecast, segmentation, competitive analysis, growth drivers, restraints, financial analysis, SWOT analysis, PORTER’s five force analysis, PESTEL analysis, market share analysis, cost-benefit analysis, challenges, restraints, strategic recommendations, and market players.

To Get more Insights, Request a Free Sample
The implantable insulin pump is surgically entrenched under the skin, while a catheter from the pump extends to the peritoneal cavity. The critical difference between eternal and implantable insulin pump is that the insulin delivered to the peritoneal cavity is quickly routed to the liver. Through the implantable insulin pump, the liver receives a high concentration of insulin, keeps a large percentage of it and permits only a small amount to pass to the rest of the body.
One of the prominent contributors includes the increasing awareness about the advantages of implantable insulin pumps created by industry experts. For instance, the Implantable Insulin Pump Foundation works actively to encourage and assist the progress of improved and technologically modern implantable insulin pumps, so that the patient receives a remarkable diabetes management solution.
The underlying diseases of the patient can cause complications and need to be monitored & treated with an utmost essentiality. For instance, congestive heart failure affects 3 to 4 million people in the US. This condition is responsible for nearly 30,000 to 40,000 deaths annually in the country. Thus, drug therapies are not hundred percent effective in such cases, and the need for innovative pumps emerge.

To Get more Insights, Request a Free Sample
The global implantable insulin pump market growth is rising at a tremendous pace owing to the factors such as the rising diabetic population, rapid urbanization in most developing as well as underdeveloped regions, and the inclination of key players towards creating awareness on the essentiality of implantable insulin pumps.
The COVID-19 outbreak has disrupted the implantable insulin pump industry during the previous year. Owing to the several restrictions on movement levied by the government all throughout the world, there was a halt in the surgeries performed. Although this situation was for a limited period, the urgent patients received the essential care. With the adoption of alternative approaches of telehealth and COVID risk scheduling techniques in hospitals, the market is set to grow amid the pandemic.
The global implantable insulin pump market is classified based on type, disease, end user, and region.
Based on the type, the global implantable insulin pump market is segmented into closed-loop insulin pump and open-loop insulin pump.
On the basis of disease, the global implantable insulin pump market is bifurcated into type 1 diabetes and type 2 diabetes.
Based on end user, the market is segmented into hospitals and home care.
| Report Attributes | Report Details |
|---|---|
| Report Name | Implantable Insulin Pump Market |
| Market Size in 2023 | USD 2.32 Billion |
| Market Forecast in 2032 | USD 4.56 Billion |
| Growth Rate | CAGR of 7.8% |
| Number of Pages | 196 |
| Key Companies Covered | Diabeloop, Apex Medical, CVS Health (Aetna Inc.), Diamesco Co., Ltd, Insulet Corporation, F. Hoffmann La Roche Ltd, Johnson & Johnson, SOOIL Developments Co. Ltd, Medtronic Plc, and Tandem Diabetes Care, among others |
| Segments Covered | By Disease, By End user and By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
| Base Year | 2023 |
| Historical Year | 2018 to 2022 |
| Forecast Year | 2024 - 2032 |
| Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The European region is estimated to hold the largest share in the global implantable insulin pump market over the forecast period. The rise in government initiatives, growing concerns regarding insulin administration, diabetes management, & injuries, rise in research activities, and the increase in the number of prominent providers are the key elements driving the growth of the market in this region. For instance, in August 2021, a team of Italian researchers published a study in the Science Robotics journal about a two-component system called PILLSID, which includes an implantable insulin pump that sits in the abdomen area and an ingestible magnetic hormone capsule to refill it. Thus, such promising research directly points towards the significant share of this region in the global implantable insulin pump market.
Moreover, North America is projected to witness considerable growth in the market due to the growing competition among the manufacturers, as well as increasing clinical trials in the field. The rising medical costs as well as the surging patient population pushes the growth of the North American implantable insulin pump market in the anticipated period. For instance, according to the American Diabetes Association, diabetes mellitus affects an approximate of 16 million people in the US. Out of these, nearly ten percent constitute type 1 diabetes, which can only be managed by injections of insulin. Such groups of patients are likely to benefit most directly from the innovative implantable insulin pump technology.
Some of the key players in the global implantable insulin pump market are:
By Disease
By End user
What Reports Provides
The market is segmented based on , By Disease (closed-loop insulin pump and open-loop insulin pump), By End user (hospitals and home care) Industry Trends and Forecast to 2032.
Global Implantable Insulin Pump Market to grow from US$ 2.32 Billion in 2023 to US$ 4.56 Billion by 2032
The Global Implantable Insulin Pump Market is projected to grow at a CAGR of 7.8%% during the forecast period of 2023 to 2032.
Diabeloop, Apex Medical, CVS Health (Aetna Inc.), Diamesco Co., Ltd, Insulet Corporation, F. Hoffmann La Roche Ltd, Johnson & Johnson, SOOIL Developments Co. Ltd, Medtronic Plc, and Tandem Diabetes Care, among others
Implantable Insulin Pump
Implantable Insulin Pump
×